Literature DB >> 34001997

Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.

Ji Hyun Lee1, Gyu Sang Yoo2, Young Cheol Yoon3, Hee Chul Park4, Hyun Su Kim1.   

Abstract

The objectives of this study were to assess changes in apparent diffusion coefficient (ADC) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) parameters after radiation therapy (RT) for bone metastases from hepatocellular carcinoma (HCC) and to evaluate their prognostic value. This prospective study was approved by the Institutional Review Board. Fourteen patients with HCC underwent RT (30 Gy in 10 fractions once daily) for bone metastases. The ADC and DCE-MRI parameters and the volume of the target lesions were measured before (baseline) and one month after RT (post-RT). The Wilcoxon signed-rank test was used to compare the parameters between the baseline and post-RT MRI. The parameters were compared between patients with or without disease progression in RT fields using the Mann-Whitney test. Intraclass correlation coefficients were used to evaluate the interobserver agreement. The medians of the ADC, rate constant [kep], and volume fraction of the extravascular extracellular matrix [ve] in the baseline and post-RT MRI were 0.67 (range 0.61-0.72) and 0.75 (range 0.63-1.43) (× 10-3 mm2/s) (P = 0.027), 836.33 (range 301.41-1082.32) and 335.80 (range 21.86-741.87) (× 10-3/min) (P = 0.002), and 161.54 (range 128.38-410.13) and 273.99 (range 181.39-1216.95) (× 10-3) (P = 0.027), respectively. The medians of the percent change in the ADC of post-RT MRI in patients with progressive disease and patients without progressive disease were - 1.35 (range - 6.16 to 6.79) and + 46.71 (range 7.71-112.81) (%) (P = 0.011), respectively. The interobserver agreements for all MRI parameters were excellent (intraclass correlation coefficients > 0.8). In conclusion, the ADC, kep, and ve of bone metastases changed significantly after RT. The percentage change in the ADC was closely related to local tumor progression.

Entities:  

Year:  2021        PMID: 34001997     DOI: 10.1038/s41598-021-90065-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  50 in total

Review 1.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  Bone metastases in hepatocellular carcinoma: an emerging issue.

Authors:  Vito Longo; Oronzo Brunetti; Stella D'Oronzo; Carmela Ostuni; Pietro Gatti; Franco Silvestris
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

3.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

4.  Initial study on in vivo conductivity mapping of breast cancer using MRI.

Authors:  Jaewook Shin; Min Jung Kim; Joonsung Lee; Yoonho Nam; Min-Oh Kim; Narae Choi; Sooyeon Kim; Dong-Hyun Kim
Journal:  J Magn Reson Imaging       Date:  2014-11-21       Impact factor: 4.813

5.  Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy.

Authors:  Jian He; Zhao-Chong Zeng; Zhao-You Tang; Jia Fan; Jian Zhou; Meng-Su Zeng; Jian-Hua Wang; Jing Sun; Bing Chen; Ping Yang; Bai-Sheng Pan
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

6.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors.

Authors:  Miho Kanda; Ryosuke Tateishi; Haruhiko Yoshida; Takahisa Sato; Ryota Masuzaki; Takamasa Ohki; Jun Imamura; Tadashi Goto; Hideo Yoshida; Keisuke Hamamura; Shuntaro Obi; Fumihiko Kanai; Shuichiro Shiina; Masao Omata
Journal:  Liver Int       Date:  2008-07-15       Impact factor: 5.828

9.  External beam radiotherapy for painful bone metastases from hepatocellular carcinoma: multiple fractions compared with an 8-Gy single fraction.

Authors:  Shinya Hayashi; Hidekazu Tanaka; Hiroaki Hoshi
Journal:  Nagoya J Med Sci       Date:  2014-02       Impact factor: 1.131

10.  Stereotactic ablative body radiotherapy for spinal metastasis from hepatocellular carcinoma: its oncologic outcomes and risk of vertebral compression fracture.

Authors:  Gyu Sang Yoo; Hee Chul Park; Jeong Il Yu; Do Hoon Lim; Won Kyung Cho; Eonju Lee; Sang Hoon Jung; Youngyih Han; Eun-Sang Kim; Sun-Ho Lee; Whan Eoh; Se-Jun Park; Sung-Soo Chung; Chong-Suh Lee; Joon Hyuk Lee
Journal:  Oncotarget       Date:  2017-08-24
View more
  4 in total

1.  Diagnostic Value and Clinical Application of Diffusion-Weighted Magnetic Resonance Imaging for Female Pelvic Lesions.

Authors:  Lulu Gao; Qing Lu; Yanting Wu
Journal:  Contrast Media Mol Imaging       Date:  2022-06-20       Impact factor: 3.009

Review 2.  Multimodal Imaging-Based Potential Visualization of the Tumor Microenvironment in Bone Metastasis.

Authors:  Jang Bae Moon; Su Woong Yoo; Changho Lee; Dong-Yeon Kim; Ayoung Pyo; Seong Young Kwon
Journal:  Cells       Date:  2021-10-25       Impact factor: 6.600

Review 3.  State-of-the-Art Imaging Techniques in Metastatic Spinal Cord Compression.

Authors:  Tricia Kuah; Balamurugan A Vellayappan; Andrew Makmur; Shalini Nair; Junda Song; Jiong Hao Tan; Naresh Kumar; Swee Tian Quek; James Thomas Patrick Decourcy Hallinan
Journal:  Cancers (Basel)       Date:  2022-07-05       Impact factor: 6.575

4.  A Cohort Study to Evaluate the Efficacy and Value of CT Perfusion Imaging in Patients with Metastatic Osteosarcoma after Chemotherapy.

Authors:  Chun Qian Zhang; Shuai Yang; Li Jing Zhang; Jian Nan Ma; De Qiang Chen
Journal:  Comput Math Methods Med       Date:  2022-07-19       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.